BNBrent A. Neuschwander-Tetri

Brent A. Neuschwander-Tetri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brent A. Neuschwander-Tetri has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease

    by Raj Vuppalanchi, Mohammad S. Siddiqui, Mark L. Van Natta, Erin Hallinan, Danielle Brandman, Kris Kowdley, Brent A Neuschwander-Tetri, Rohit Loomba, Srinivas Dasarathy, Manal Abdelmalek, et al.

    Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibration‐controlled transient elastography studies reported high failure rates in patients with nonalcoholic fatty liver disease. We examined the performance characteristics of the FibroScan 502 Touch with two probes, medium (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter setting. A total of 1,696 exams were attempted in 992 patients (body mass index, 33.6 ± 6.5 kg/m2) with histologically confirmed nonalcoholic fatty liver disease. Simultaneous assessment of LSM and CAP was performed using the FibroScan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by either a single operator (87%) or two operators (13%). Failure was defined as the inability to obtain a valid examination. An examination was considered unreliable if LSM interquartile range/median was >30%. Significant disagreement between two readings was defined as >95% limits of agreement between two readings. A total of 1,641 examinations yielded valid results with a failure rate of 3.2% (55/1,696). The proportion of unreliable scans for LSM was 3.9%. The proportion of unreliable scans with operator experience in the top quartile (≥59 procedures) was significantly lower than that in the lower three quarters combined (1.6% versus 4.7%,P= 0.02 by Fisher's exact test). The significant disagreement between first and second readings for LSM and CAP when obtained back to back was 18% and 11%, respectively.Conclusion:Vibration‐controlled transient elastography for estimation of LSM and CAP can be successfully deployed in a multicenter setting with low failure (3.2%) and high reliability (>95%) rates and high reproducibility. (Hepatology2018;67:134‐144).


  • Top Cited Papers
    Open Access

    Non-alcoholic fatty liver disease

    by Brent A. Neuschwander-Tetri

    Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation. This overview briefly summarizes the most recent data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if successfully understood and exploited would not only address fatty liver disease but also the other components of the metabolic syndrome such as obesity, diabetes and dyslipidemia.


  • Future Treatments of NASH

    by Brent A. Neuschwander-Tetri


  • Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply

    by Brent A Neuschwander-Tetri, Mark L Van Natta, James Tonascia, Elizabeth M Brunt, David E Kleiner


  • Top Cited Papers

    Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

    by Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed, et al.


  • Carbohydrate intake and nonalcoholic fatty liver disease

    by Brent A. Neuschwander-Tetri

    Carbohydrate consumption has been implicated in the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). Reviewed here is basis for this relationship and the recent additional evidence that excessive dietary carbohydrate consumption, especially excessive fructose or sucrose consumption, is playing a role in the epidemic of NAFLD. A recent cross-sectional epidemiological study has linked fructose consumption to the severity of fibrosis in patients with NAFLD. Clinical trials have shown that consumption of fructose-containing beverages, either has fructose or sucrose, contribute to the development of NAFLD compared to isocaloric alternatives, and that genetic polymorphisms that increase the entry of glucose into lipogenic pathways are associated with fatty liver disease. New animal studies provide additional evidence on the role of carbohydrate-induced de-novo lipogenesis and the gut microbiome in fructose-induced NAFLD. Data also suggest that fructose-induced uric acid production in the liver also plays a role in NAFLD independent of the role of fructose as a substrate for lipogenesis. Epidemiological studies, clinical trials, and animal studies continue to point to excess dietary carbohydrate, and especially fructose, in contributing to the risk factors for NAFLD.


  • 804 Hepatic Zonation in a Nonalcoholic Steatohepatitis Mouse Model

    by Won Jae Huh, Joseph M. Albanese, Lorena Salavaggione, Qiang Liu, Brent A. Neuschwander-Tetri, Elizabeth M. Brunt

  • Dietary trans‐Fatty Acid Induced NASH is Normalized Following Loss of trans‐Fatty Acids from Hepatic Lipid Pools

    by Brent A. Neuschwander‐Tetri, David A. Ford, Sahaja Acharya, George Gilkey, Metin Basaranoglu, Laura H. Tetri, Elizabeth M. Brunt

    Previous experiments in mice showed that dietary trans‐fats could play a role in non‐alcoholic steatohepatitis (NASH) yet little is known about the accumulation trans‐fats in hepatic lipid pools in relationship to liver injury. NASH is also associated with obesity yet improves with only modest weight loss. To distinguish the role of obesity versus sustained consumption of a trans‐fat containing diet in causing NASH, mice with obesity and NASH induced by consuming a high trans‐fat diet for 16 weeks were subsequently fed standard chow or maintained on trans‐fat chow for another 8 weeks. The accumulation, partitioning and loss of trans‐fats in the major hepatic lipid pools during and after trans‐fat consumption were determined. Obese mice switched to standard chow remained obese but steatohepatitis improved. trans‐fats were differentially incorporated into the major hepatic lipid pools and the loss of trans‐fats after crossover to control chow was greatest in the cholesteryl ester pool. In summary, dietary changes can improve the biochemical and histopathological changes of NASH despite persistent obesity in mice. Analysis of hepatic lipids confirmed that dietary trans‐fats accumulate in the major lipid pools and are released differentially with diet normalization. The substantial loss of trans‐fats from the cholesteryl ester pool in parallel with improvement in NASH suggests that this pool of trans‐fats could play a role in the pathogenesis of NASH.